Aurobindo and Lannett expand their generics portfolios

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Aurobindo and Lannett expand their generics portfolios

Generics/News | Posted 15/06/2018 0 Post your comment

Both Indian generics maker Aurobindo Pharma (Aurobindo) and US generics company Lannett have announced efforts to increase their generics portfolios.

Both Indian generics maker Aurobindo Pharma (Aurobindo) and US generics company Lannett have announced efforts to increase their generics portfolios.

Aurobindo has made a bid of around US$1.6 billion to buy the dermatology generics business from Novartis. The portfolio includes an array of dermatology brands, production facilities and associated infrastructure, mostly in the US. Novartis is considering the sale of its dermatology generics business under the Sandoz brand as it seeks to sell some of its less profitable businesses.

Aurobindo acquired generics commercial operations in seven markets in Western Europe from Actavis back in 2014 [1]. Then in January 2017, it agreed to buy Portugal’s Generis Farmaceutica from Magnum Capital Partners for Euros 135 million.

Lannett announced on 7 May 2018 that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International (Endo) for an upfront payment plus future milestone payments. The portfolio primarily consists of oral solutions with a few semi-solid products. For the 12 months ending March 2018, combined sales of the acquired products were in excess of US$175 million, according to IMS. The company expects to begin launching the products, under the Lannett label, as soon as the transfer activities are completed and appropriate regulatory filings are made. Lannett estimates that this will be in the second half of fiscal 2019.

Lannett also acquired the US specialty generics business, Kremers Urban, from Belgium-based biopharmaceutical company UCB in September 2015 for US$1.23 billion in cash plus contingent payments [2].

Lannett to co-develop biosimilar insulin product with Chinese partner

References
1. GaBI Online - Generics and Biosimilars Initiative. Aurobindo to acquire seven generics businesses from Actavis [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jun 15]. Available from: www.gabionline.net/Pharma-News/Aurobindo-to-acquire-seven-generics-businesses-from-Actavis
2. GaBI Online - Generics and Biosimilars Initiative. UCB sells generics unit to Lannett [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jun 15]. Available from: www.gabionline.net/Pharma-News/UCB-sells-generics-unit-to-Lannett

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Lannett, LiveMint